TET2 and cancer: Although this review focuses on TET2 mutation, there is evidence that mutations in other critical genes can also give rise to a global genomic hypermethylation phenotype in both hematological and nonhematological cancers, including WT1 in AML [109] and IDH1/2 in AML [110] and glioma [111].